Skip to content
‹ Back to IndustriesHealthcare

Joan Oloff is Making Fashion More Functional

All too often, our choice of wardrobe comes down to function or fashion. We sacrifice comfort to look good, or we sacrifice taste so that we can be comfortable during long days on the job. Increasingly, however, companies are seeking to create pants, dress shirts and shoes that combine runway aesthetic with around-the-house comfort. In…

This story was produced through MarketScale. See how Healthcare teams put it to work with Executive Thought Leadership.

·
Share

Free workspace

Turn your Healthcare expertise into content.

Record interviews, organize footage, and write with AI on a free trial of the MarketScale platform for qualifying companies. No demo required, no credit card.

Try it Free

All too often, our choice of wardrobe comes down to function or fashion. We sacrifice comfort to look good, or we sacrifice taste so that we can be comfortable during long days on the job. Increasingly, however, companies are seeking to create pants, dress shirts and shoes that combine runway aesthetic with around-the-house comfort. In a fashion landscape dominated by established brands, it can be difficult for a start-up to stand out. By providing customers with clothing and accessories that look great but can also be worn on the job, new brands are able to break through this barrier.

Few designers exemplify this innovative spirit as much as Joan Oloff. A podiatrist by training, Joan set out to make the first line of orthopedically correct high heels. After seeing the issues that traditional high heels cause in her patients, Joan knew there had to be a way to design beautiful shoes that wouldn’t negatively impact the health of the wearer’s feet down the road.

The challenge was taking elements already common in athletic and walking shoes, like offloading pressure points, incorporating shock-absorption and providing proper support, and finding a way to implement these same features in heels. Over the course of four years, Joan worked with designers and manufacturers, in both Los Angeles and Italy, to make her line of shoes fit her standards. It was difficult. The manufacturers didn’t want to do things her way. But she pushed ahead.

“If I’m not going to be a game-changer, if I’m not going to disrupt the way high heels are made, there’s no point for me to do this,” Joan said in an interview with the San Francisco Chronicle.

Her perseverance paid off and today, Joan Oloff’s shoes have built-in arch support, cushioning material in the ball of the foot and a lower heel pitch, all of which allow the entire foot to comfortably share the body’s weight. Perhaps the most impressive aspect of her line is simply the diversity of options. Made by hand, the latest collection has everything from sandals to knee-high boots. The beauty of the line, combined with the comfort of the shoes, have garnered Joan a loyal following. One surgeon in Santa Fe owns ten pairs of the shoes as they allow her to work without discomfort be it in her office, visiting patients or even conducting an hours-long surgical procedure.

While her customers all praise her shoes, Joan also has proof to back up her claims that she makes healthy heels. Using CurveBeam’s revolutionary pedCAT technology, Joan is able to show weight-bearing CT scans of her shoes in action. When compared side-by-side with the same scans of someone wearing standard heels, it is obvious that Joan’s shoes provide evenly distributed support and stable positioning while other shoes have toe crimping and no arch support, creating a painful experience for the wearer.

Just like Joan Oloff, CurveBeam is dedicated to changing the game. By creating innovative 3D scanning technology that provides a complete view of a patient’s lower extremities, the pedCAT has given podiatrists, physical therapists, and others the ability to give their patients the proper treatment they need. Learn more about pedCAT here.

Read more at curvebeam.com

Your experts belong here

Every story in MarketScale Healthcare starts with a company putting its clinicians, service-line leaders, and field engineers on the record. Buyers are already reading this topic. The only question is whose experts they find.

Service-line buyers vet vendors quietly, and your clinicians become the proof they find while doing it.

Book DemoSee how it works15 minutes, straight to a calendar.
B2B Weekly

The week in Healthcare, and sixteen other industries, every Monday.

Ten stories, one-line takes, five minutes. Free.

Healthcare: are you visible to AI?

Before they reach out, Healthcare buyers ask AI engines which vendors to trust. Explore how your experts, customers, and partners can become useful content for buyers and AI search.

Free Trial

You just read one Healthcare expert. Your company is full of them.

This article was produced through MarketScale. The same platform turns your clinicians, service-line leaders, and field engineers into the articles, video, and social content Healthcare buyers are searching for. Start a free trial and see it with your own people. For qualifying companies, no credit card, no demo required.

NPS +73 · 1,000+ creators · 38+ countries

What your free trial includes

Hands-on access to the MarketScale platform
Media requests to your crowd, remote recording, AI writing tools
No demo required. No credit card.
For qualifying companies. Company confirmation required.

More Healthcare Insights

Pharma rates its follow-through on diagnostic data 5.2 out of 10 in Diaceutics survey

Pharma rates its follow-through on diagnostic data 5.2 out of 10 in Diaceutics survey

In a Diaceutics survey of 125 US pharma leaders, respondents rated the significance of converting diagnosis into treatment to future commercial success at an average of 7.5 out of 10. They rated their organizations' effectiveness at turning diagnostic insights into coordinated action at just 5.2 out of 10. Separate Diaceutics lung cancer research found the largest gap now occurs at the point of treatment decision.

  • 01Pharma leaders rated their confidence in identifying eligible patients at 6.6 out of 10, their visibility across the patient journey at 5.4 and their effectiveness at turning diagnostic insights into coordinated action at 5.2. The low last score could point to the treatment decision, where Diaceutics' lung cancer research found the largest gap now occurs.
  • 02In US advanced non-small cell lung cancer, Diaceutics found overall patient loss virtually unchanged at 65.1% in 2023 versus 64.4% in 2019, while patient loss at the point of treatment decision rose from 29.2% to 43.3%. For operators, a flat headline rate could hide one step getting worse.
  • 03Senior leaders from several top 20 pharma companies argue diagnostic planning belongs early in development and commercialization, rather than as a testing and adoption fix after launch.

Nov 22, 2026

Frequent use of clinical AI tools rose to 34% in Elsevier's 2026 clinician survey

Elsevier's Clinician of the Future 2026 survey found 49% of clinicians use AI at work. Purpose-built clinical AI is gaining fast. Its frequent use rose from 22% in 2025 to 34% this year, yet 41% of nurses say their views are rarely or never sufficiently considered in important organizational decisions.

  • 01A sharper vendor question: which evidence base grounds the tool's answers, and can a clinician see that source at the moment of use? Transparency and authoritative data top clinicians' own list of what builds trust.

Nov 22, 2026

Zoom's stake in Medaica aims to bring the physical exam into video visits

Zoom Ventures made an undisclosed strategic investment in Medaica, whose FDA-cleared M1 telehealth stethoscope supports real-time remote heart and lung auscultation. Zoom already integrates with EHRs including Epic, Oracle Cerner Millennium and Athenahealth, but an investment is not an integration and no combined product has been announced. Cardiology follow-ups and care facilities are highlighted as likely early use cases.

  • 01Video gave telehealth the patient's face; an FDA-cleared remote stethoscope adds the heartbeat, and Zoom now has a financial stake in that second layer.
  • 02Today's cleared capability is real-time heart and lung auscultation; the wider mix of third-party devices, AI analysis and decision support is still in development.
  • 03For health systems with elderly or rural cardiology panels, the sharper vendor question is how exam findings reach the EHR record of the visit.

Nov 21, 2026

Explore More Healthcare Insights

Read more expert perspectives from across Healthcare.

Browse Healthcare Hub

For B2B teams

Your experts could be publishing here

Stories like this one run on content MarketScale captures from real practitioners. See how your team's expertise becomes coverage in Healthcare and beyond.

Book a Demo

Or call us. No forms required. We pick up. 214-945-2512